We are live on ! Find out more
INTS icon

Intensity Therapeutics
INTS

9 hedge funds and large institutions have $1.19M invested in Intensity Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

875% more capital inflows, than outflows

Capital inflows: $1.65M | Capital outflows: $169K

700% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 1

350% more funds holding

Funds holding: 2 → 9 (+7)

1.97% more ownership

Funds ownership: 0.21% → 2.18% (+2%)

Holders
9
Holders Change
+7
Holders Change %
+350%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Hohimer Wealth Management
Hohimer Wealth Management
Washington
+$1.03M
2
Sigma Planning Corp
Sigma Planning Corp
Michigan
+$266K
3
Millennium Management
Millennium Management
New York
+$137K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$128K
5
BlackRock
BlackRock
New York
+$56.6K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$169K

INTS Hedge Fund Activity: Q3 2023 in Review

9 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q3 2023, worth a combined $1.19M — up 599% from $170K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new INTS positions and 1 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Hohimer Wealth Management, opening a new position worth an estimated $1.03M. The largest seller was Walleye Capital, exiting entirely with an estimated $169K sold.

  • 9 institutional investors held Intensity Therapeutics (INTS) as of Q3 2023, up from 2 in Q2 2023.
  • Funds reported $1.19M of Intensity Therapeutics stock for Q3 2023, up 599% quarter-over-quarter.
  • 8 funds opened new Intensity Therapeutics positions in Q3 2023 and 1 closed out, a net change of +7 holders.
  • The largest Intensity Therapeutics buyer in Q3 2023 was Hohimer Wealth Management, an estimated $1.03M added.
  • The largest Intensity Therapeutics seller in Q3 2023 was Walleye Capital, an estimated $169K sold.

Based on aggregated 13F filings for Q3 2023.